Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Effects of interferon-alpha 2b treatment on ex vivo differentiation of mast cells from circulating progenitor cells in a patient with systemic mastocytosis
Autore:
Schernthaner, GH; Spanblochl, E; Sperr, WR; Sillaber, C; Semper, H; Jurecka, W; Hagen, M; Wolff, K; Chott, A; Lechner, K; Valent, P;
Indirizzi:
Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, A-1090 Vienna, Austria Univ Vienna Vienna Austria A-1090 & Hemostaseol, A-1090 Vienna, Austria Univ Vienna, Dept Dermatol, Vienna, Austria Univ Vienna Vienna AustriaUniv Vienna, Dept Dermatol, Vienna, Austria Univ Vienna, Dept Clin Pathol, Vienna, Austria Univ Vienna Vienna Austria iv Vienna, Dept Clin Pathol, Vienna, Austria
Titolo Testata:
ANNALS OF HEMATOLOGY
fascicolo: 12, volume: 79, anno: 2000,
pagine: 660 - 666
SICI:
0939-5555(200012)79:12<660:EOI2TO>2.0.ZU;2-9
Fonte:
ISI
Lingua:
ENG
Soggetto:
BONE-MARROW; IFN-GAMMA; PERIPHERAL-BLOOD; HUMAN TRYPTASE; ALPHA; DISEASE; CD34+; OSTEOPOROSIS; ANAPHYLAXIS; PRECURSORS;
Keywords:
mastocytosis; progenitor cells; interferon-alpha; tryptase; histamine;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
47
Recensione:
Indirizzi per estratti:
Indirizzo: Valent, P Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, Waehringer Guertel 18-20, A-1090 Vienna, Austria Univ Vienna Waehringer Guertel 18-20 Vienna Austria A-1090 tria
Citazione:
G.H. Schernthaner et al., "Effects of interferon-alpha 2b treatment on ex vivo differentiation of mast cells from circulating progenitor cells in a patient with systemic mastocytosis", ANN HEMATOL, 79(12), 2000, pp. 660-666

Abstract

Interferon (IFN)-alpha a known inhibitor of myelopoiesis. is increasingly used to treat patients with systemic mastocytosis (SM). However, the mechanisms of IFN-ce effects on mast cell (MC) growth remain unknown, and the treatment responses may be variable. In the present study, factor-dependent exvivo differentiation of MCs from peripheral blood mononuclear cells (PBMNCs) was analyzed in a patient with SM treated with IFN-alpha 2b (3 million U/day). The patient exhibited an extensive MC infiltration in his bone marrow (BM) and increasing serum total tryptase levels (spiking to > 1400 ng/ml). PBMNCs were collected before and during IFN-alpha 2b treatment and cultured in the presence or absence of stem cell factor (SCF, 100 ng/ml) for 42 days. In the absence of SCF, no MC growth was detectable. However, in the presence of SCF, MC containing tryptase appeared in the cultures. Treatment with IFN-a2b resulted in a time-dependent decrease in SCF-inducible formation of MCs from PB progenitor cells in vitro. Also, during IFN-alpha 12b treatment, blood histamine concentrations decreased. Serum total tryptase levels initially increased despite IFN-2ab treatment. However after a latency period of a few months, tryptase concentrations declined and then reached a plateau. In healthy individuals, the SCF-induced in vitro growth of MCs fromtheir progenitor cells was also inhibitable by the addition of IFN-alpha 2b. In summary. our data show that IFN-alpha 2b can exhibit inhibitory effects on factor-dependent growth of MC progenitor cells. However, it still remains open which of the patients with mastocytosis can benefit from long-term IFN-alpha treatment.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/09/20 alle ore 05:34:47